CRIS: the cash flow

MyFinsight

For the year ending 2025-12-31, CRIS had -$14,936K decrease in cash & cash equivalents over the period.

Cash Flow	2025-12-31
Net loss	-7,582
Depreciation and amortization	169
Non-cash lease expense	1,273
Stock-based compensation expense	4,018
Non-cash activity related to the sale of future royalties prior to the sale of erivedge	360
Gain on release of liability related to sale of future royalties associated with sale of assets	27,189
Amortization of premiums and discounts on investments	0
Accounts receivable	1,032
Prepaid expenses and other assets	-1,572
Accounts payable and accrued and other liabilities	2,546
Operating lease liability	-1,336
Total adjustments	-19,619
Net cash used in operating activities	-27,201
Purchases of investments	0
Sales and maturities of investments	0
Proceeds from the sale of erivedge	2,500
Net cash provided by investing activities	2,500
Proceeds from issuance of common stock, pre-funded warrants, and common warrants, net of issuance costs	15,352
Payment of liability of future royalties, net of imputed interest	5,587
Net cash provided by financing activities	9,765
Net decrease in cash and cash equivalents and restricted cash	-14,936
Cash and cash equivalents and restricted cash, beginning of period	20,541
Cash and cash equivalents and restricted cash, end of period	5,605

Unit: Thousand (K) dollars (except for numbers of shares and EPS).